Oncotarget

Research Papers:

Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins

Daniela Heilos, Clemens Röhrl, Christine Pirker, Bernhard Englinger, Dina Baier, Thomas Mohr, Michaela Schwaiger, Shahid Muhammad Iqbal, Sushilla van Schoonhoven, Kristaps Klavins, Tanja Eberhart, Ursula Windberger, Judith Taibon, Sonja Sturm, Hermann Stuppner, Gunda Koellensperger, Rita Dornetshuber-Fleiss, Walter Jäger, Rosa Lemmens-Gruber and Walter Berger _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:25661-25680. https://doi.org/10.18632/oncotarget.25432

Metrics: PDF 702 views  |   HTML 3159 views  |   ?  


Abstract

Daniela Heilos1,2, Clemens Röhrl3, Christine Pirker1, Bernhard Englinger1, Dina Baier1,4, Thomas Mohr1, Michaela Schwaiger5, Shahid Muhammad Iqbal2, Sushilla van Schoonhoven1, Kristaps Klavins6, Tanja Eberhart3, Ursula Windberger4, Judith Taibon7, Sonja Sturm7, Hermann Stuppner7, Gunda Koellensperger5,8, Rita Dornetshuber-Fleiss1,2, Walter Jäger9, Rosa Lemmens-Gruber2 and Walter Berger1

1Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria

2Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria

3Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria

4Decentralized Biomedical Facilities of the Medical University of Vienna, Vienna, Austria

5Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria

6BIOCRATES Life Sciences AG, Innsbruck, Austria

7Institute of Pharmacy, Pharmacognosy and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria

8Vienna Metabolomics Center, University of Vienna, Vienna, Austria

9Department of Pharmaceutical Chemistry, Division of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria

Correspondence to:

Walter Berger, email: walter.berger@meduniwien.ac.at

Keywords: cholesterol synthesis pathway; cancer cell resistance; destruxins; mycotoxins; cell membrane alterations

Received: January 15, 2018    Accepted: April 25, 2018    Published: May 22, 2018

ABSTRACT

Destruxins, secondary metabolites of entomopathogenic fungi, exert a wide variety of interesting characteristics ranging from antiviral to anticancer effects. Although their mode of action was evaluated previously, the molecular mechanisms of resistance development are unknown. Hence, we have established destruxin-resistant sublines of HCT116 colon carcinoma cells by selection with the most prevalent derivatives, destruxin (dtx)A, dtxB and dtxE. Various cell biological and molecular techniques were applied to elucidate the regulatory mechanisms underlying these acquired and highly stable destruxin resistance phenotypes. Interestingly, well-known chemoresistance-mediating ABC efflux transporters were not the major players. Instead, in dtxA- and dtxB-resistant cells a hyper-activated mevalonate pathway was uncovered resulting in increased de-novo cholesterol synthesis rates and elevated levels of lanosterol, cholesterol as well as several oxysterol metabolites. Accordingly, inhibition of the mevalonate pathway at two different steps, using either statins or zoledronic acid, significantly reduced acquired but also intrinsic destruxin resistance. Vice versa, cholesterol supplementation protected destruxin-sensitive cells against their cytotoxic activity. Additionally, an increased cell membrane adhesiveness of dtxA-resistant as compared to parental cells was detected by atomic force microscopy. This was paralleled by a dramatically reduced ionophoric capacity of dtxA in resistant cells when cultured in absence but not in presence of statins. Summarizing, our results suggest a reduced ionophoric activity of destruxins due to cholesterol-mediated plasma membrane re-organization as molecular mechanism underlying acquired destruxin resistance in human colon cancer cells. Whether this mechanism might be valid also in other cell types and organisms exposed to destruxins e.g. as bio-insecticides needs to be evaluated.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25432